SEC Form 4 · accession 0000899866-15-000147
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin Mackay
Officer — EVP & Global Head of R&D
Period of report
Aug 3, 2015
Accepted (ET)
Aug 5, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per share | Aug 3, 2015 | M | 28,125 | $104.86 | A | 61,018 | D | |
| Common Stock, par value $.0001 per share | Aug 3, 2015 | M | 15,375 | $176.80 | A | 76,393 | D | |
| Common Stock, par value $.0001 per shareF1 | Aug 3, 2015 | S | 17,100 | $197.24 | D | 59,293 | D | |
| Common Stock, par value $.0001 per shareF2 | Aug 3, 2015 | S | 17,518 | $196.48 | D | 41,775 | D | |
| Common Stock, par value $.0001 per shareF3 | Aug 3, 2015 | S | 8,882 | $195.19 | D | 32,893 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common Stock | $104.86 | Aug 3, 2015 | M | 28,125 | D | May 13, 2014 | May 13, 2023 | Common Stock, par value $.0001 per share | 28,125 | 37,500 | D |
| Option to Purchase Common Stock | $176.80 | Aug 3, 2015 | M | 15,375 | D | Feb 28, 2015 | Feb 28, 2024 | Common Stock, par value $,0001 per share | 15,375 | 33,825 | D |
Explanation of responses
- F1This transaction was executed in multiple trades through a broker-dealer at prices ranging from $197.00 - $197.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- F2This transaction was executed in multiple trades through a broker-dealer at prices ranging from $196.00 - $196.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- F3This transaction was executed in multiple trades through a broker-dealer at prices ranging from $195.00 - $195.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.